The Institute for Clinical and Economic Review on Oct. 25 released an evidence report on four extended-release medications for treatment of opioid use disorder.
The report, according to a press release, assessed the comparative clinical effectiveness and value of Titan’s Probuphine, a buprenorphine implant, Alkermes’ Vivitrol, an extended-release naltrexone injection, and two extended-release buprenorphine injections: CAM2038 and Sublocade.
“Opioid use disorder is devastating families and communities in the U.S.,” ICER Chief Medical Officer Dr. David Rind said in a statement. “Extended-release medications have generated clinical interest because of their potential to improve individuals’ ability to remain in treatment.”
The New England Comparative Effectiveness Public Advisory Council will discuss the report during a Nov. 8 meeting, according to the release.